Fig. 7. Co-treatment with epigenetic inhibitor with JAK/STAT pathway inhibitors in SUDHL1 cells.

(A, B) SUDHL1 cells were treated with the indicated concentrations of (A) azacytidine (2.5 µM) ± ruxolitinib (2.5 µM), (B) azacytidine (2.5 µM) ± WHIP-154 (2.5 µM) and cells were treated 48 h and survival was assessed as described. (C, D) SUDHL1 cells were treated with (C) romidepsin (2.5 nM) + ruxolitinib (2.5 or 5.0 µM) (D), romidepsin (2.5 nM) + WHIP-154 (2.5 and 5.0 µM) for 48 h and survival was assessed as described before. Presented in the bar graphs are mean ± standard error of three independent experiments. *P-value≤0.05 was considered significant